PORTFOLIO
PORTFOLIO COMPANIES
United Immunity, Co., Ltd.
-
- Chairman and Founder:
- Naozumi Harada
-
- President:
- Masato Kishida
COMPANY PROFILE
Uniting the Power of Nanotechnology and Immunity for the Fight to Cancer
Our research team has been working on the discovery of new cancer immunotherapy that can treat immunologically “cold tumor”. Our team found that in cold tumor, tumor-associated macrophages (TAMs) were specifically inactive and did not exert their antigen presentation function.
Our proprietary drug delivery system “T-ignite®” can bind TAMs specifically and deliver functional drug candidates to reprogram TAMs and to activate T cell. We aim to overcome intractable cold cancer that is refractory to existing treatments such as immune checkpoint inhibitors by developing novel combination immunotherapies utilizing T-ignite and other immunotherapies and/or molecular-targeted therapies.
Our proprietary drug delivery system “T-ignite®” can bind TAMs specifically and deliver functional drug candidates to reprogram TAMs and to activate T cell. We aim to overcome intractable cold cancer that is refractory to existing treatments such as immune checkpoint inhibitors by developing novel combination immunotherapies utilizing T-ignite and other immunotherapies and/or molecular-targeted therapies.
COMPANY STORY
Origin
Founding scientist and inventor Dr. Naozumi Harada founded United Immunity in 2017 to utilize the results of Professor Kazunari Akiyoshi's nanogel engineering research at Kyoto University.
Strength
TAMs specific targeting technology, variety of functional drug candidates to combine with nanogel
UTEC’s value add
Hands-on support including advice on R&D plans, structuring corporate governance, and recruitment of management talents
-
Overview of T-ignite
-
TAMs targeting (intravenous injection)